41 results about "Endothelin 1" patented technology

Chronic glaucoma, cataract, ocular and periocular aging are treated and prevented by the administration of agents that affect metabolic subsystems such as (i) mitochondrial bioenergetics, (ii) free radical moderation and glutathione maintenance, (iii) constitutive nitric oxide/endothelin-1 balance, and (iv) calcium wave signaling and associated neuronal excito-toxicity. Included among the agents are tetrahydrobiopterin, R-alpha-lipoic acid, coenzyme Q10, 17 alpha-estradiol, and glutathione.

The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.

Cell transplantation for constructing biological heart pacemaker is used embryo source dry/ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

Sequences in human preproendothelin-1 mRNA are described against which antisense oligonucleotides can be used to inhibit the synthesis of endothelin-1. This inhibition of endothelin-1 synthesis may be used to treat diseases where excess production of endothelin-1 is an underlying cause of the symptoms.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Endothelin-1, Somatotropin, and Interleukin-13 as diagnostic and prognostic biomarkers in renal injuries.

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and/or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

The invention provides an anti-alcohol drink used for protecting liver and gastric mucosa, and a preparation method of the drink. The method comprises the steps of mixing semen hoveniae, radix salviae miltiorrhizae, radix puerariae, radix codcnopsitis pilosulas, pericarpium citri reticulatae, fructus lycii, flos puerariae, fructus crataegi, radix glycyrrhizae and fructus ligustri lucidi according to a weight ratio, and decocting a mixture twice by using water with the weight 8 times that of the mixture; and combining filter liquors and performing reduced pressure concentration to prepare fluid extract. By building models of acute liver injury and gastric mucosal lesion of mice, tissue forms of the liver and the gastric mucosa are checked, and indexes such as ALT, AST, ALB and the like in serum are measured; an immunohistochemical method is used for detecting expression situations of MnSOD, BCL-2 and Caspase-3 of the liver; a fluorescent PCR method is used for detecting gene expression levels of Nrf2 and SOD of liver tissues; gastric mucosal lesion indexes, inhibition rates and content of endothelin-1 and the like of the gastric mucosa of each group of mice are measured; the protection effect of the drink on the liver and gastric mucosa of a mouse is comprehensively researched; and experimental data proves that the drink can improve oxidation resistance of the liver and inhibit liver cell apoptosis, and has the effect of protecting gastric mucosal lesion.

The invention discloses a preparation method and application of an RNA interfering medicine for treating a pulmonary hypertension syndrome and an efficacy validation method thereof. The preparation method comprises the following steps: firstly, establishing a slow virus expression vector, namely HIF-1alpha-shRNAi; secondly, packaging HIF-1alpha-shRNAi recombinant plasmids into a preparation; thirdly, injecting the plasmids into bodies of broilers, silencing an HIF-1alpha gene, inhibiting expressions of a vascular endothelial growth factor (VEGF), endothelin 1 (ET 1) and an insulin-like growth factor II (IGF - II) of a downstream gene and the like, controlling a pulmonary vascular remodeling (PVR) phenomenon, reducing damage of a cardiopulmonary function and ascites formation and finally achieving the clinical treatment to the pulmonary hypertension syndrome. The preparation method has the advantages of specificity, high efficiency and multifunctionality and the like on an aspect of treatment.

A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and/or inhibiting its binding to its ET_A and/or ET_B receptors are also provided.

The invention discloses polypeptide having effect of resisting tumors and use of the polypeptide. The polypeptide is named as TAT-ETA1, is polypeptide as shown as (1) or (2): (1) polypeptide of the 12-69th amino acid residues of an amino acid sequence as shown in SEQ ID NO:1; and (2) polypeptid of an amino acid sequence as shown in SEQ ID NO:1. The polypeptide TAT-ETA1 provided by the invention isfrom the carboxyl terminal of A type endothelin receptor 1(ETAR), when the TAT-ETA1 can act on ETAR in endothelin 1, the TAT-ETA1 can be combined with the carboxyl terminal of the Beta-arrestin 1 (ETAR) competitively to interfere interact between ETAR and beta-arrestin 1 so as to relieve cancer cell migration, invasion induced by the beta-arrestin 1, reverse tolerance during chemotherapy and thelike. The polypeptide TAT-ETA1 has clinical application potential for treatment of cancer.

The present invention relates to a method for increasing the stemness of human mesenchymal stem cells and, more particularly, to: a method for increasing the stemness of human mesenchymal stem cells by means of endothelin-1 treatment; the human mesenchymal stem cells having increased stemness by using the method; and a composition for increasing the stemness of human mesenchymal stem cells, containing endothelin-1 as an active ingredient. In the present invention, it is confirmed that the expression of a stemness marker is increased and that a stem cell characteristic is improved such as the length of telomeres being extended, by treating human mesenchymal stem cells with endothelin-1, and thus cellular life span is extended, aging is inhibited, and the growth and viability of cells are increased, thereby enabling mass culturing of human mesenchymal stem cells such that human mesenchymal stem cells are expected to be used effectively in cell therapy or regenerative medicine.

A process for testing the susceptibility of primary hypertension includes detecting if there are variations in endotheline (gene EDN1, transcript and protein of an individual and determining its high susceptibility if there are. Its reagent kit is also disclosed.

Subject of the present invention is an in vitro method for the alternative assessment of peak oxygen consumption (VO2) for a subject not having a heart failure by measuring Pro-Endothelin-1 (ProET-1) or fragments thereof.